Россииское кардиологическое общество Российское научное медицинское общество терапевтов Антигипертензивная лига
 Скачать 3.62 Mb.
|
|
Survey. Arthritis Rheum. 2007;57:109–15.1 426. Novak S, Melkonian AK, Patel PA, Kleinman NL, Joseph-Ridge N, Brook RA. Metabolic syndrome-related conditions among people with and without gout: prevalence and resource use. Curr Med Res Opin. 2007;23:623–30. 158 427. Dao HH, Harun-Or-Rashid M, Sakamoto J. Body composition and metabolic syndrome in patients with primary gout in Vietnam. Rheumatology (Oxford). 2010;49:2400–7. 428. Humphreys JH, Verstappen SM, Mirjafari H, et al. Association of morbid obesity with disability in early inflammatory polyarthritis: Results from the Norfolk Arthritis Register. Arthr Care Res, 2013;65(1):122-6. 429. Wolf F, Michaud K. The effect of body mass index on mortality and clinical status in rheumatoid arthritis. Arthr Care Res, 2012; 64(10):1471-9. 430. Metsios GS, Stavropoulos-Kalinouglou A, Panoulas VF, et al. Rheumatoid cachexia and cardiovascular disease. Clin Exp Rheumatol, 2009;27(6):991-4. 431. Galic S, Oakhill JS, Steinberg GR. Adipose tissue as an endocrine organ. Mol. Cell. Endocrinol, 2010; 316(2): 129-39 432. Crowson CS, Matteson EL, Davis III JM, Gabriel SE. Contribution of obesity to the rise in incidence of rheumatoid arthritisObesity fuels the upsurge in rheumatoid arthritis. Arthr Care Res, 2013 Jan;65(1):71-7. 433. Symmons DP, Bankhead CR, Harrison BJ, et al. Blood transfusion, smoking, and obesity as risk factors for the development of rheumatoid arthritis: results from a primary care-based incident case-control study in Norfolk, England. Arthr Rheum, 1997;40:1955-61. 434. Giles JT, Allison M, Blumenthal RS, et al. Abdominal adiposity in rheumatoid arthritis. Association with cardiometabolic risk factors and disease characteristics. Arthr Rheum, 2010;62(11):3173-3182. 435. Inaba M, Tanaka K, Goto H, et al. Independent association of increased trunk fat with increased arterial stiffening in postmenopausal patients with rheumatoid arthritis. J Rheumatol, 2007;34:290-5. 436. Ajeganova S, Andersson ML, Hafstrom I. Association of obesity with worse disease severity in rheumatoid arthritis as well as with comorbidities: A long-term followup from disease onset. Arthr Care Res, 2013;65(1):78-87 437. Westhoff G, Rau R, Zink A. Radiographic joint damage in early rheumatoid arthritis is highly dependent on body mass index. Arthr Rheum, 2007;56(11):3575-82. 438. van der Helm-van Mil AH, van der Kooij SM, Allaart CF, et al. A high body mass index has a protective effect on the amount of joint destruction in small joints in early rheumatoid arthritis. Ann Rheum Dis, 2008;67(6):769-74. 439. Российские клинические рекомендации. Ревматология / под ред. Е.Л.Насонова. – М.: ГЭОТАР-Медиа, 2017. – 464с. 440. Драпкина О. М., Ивашкин В. Т. Эпидемиологические особенности неалкогольной жировой болезни печени в России (результаты открытого многоцентрового проспективного исследования-наблюдения DIREGL 01903) // Рос. журн. гастроэнтерол, гепатол, колопроктол. 2014. Т. 24, № 4. С. 32–38. 441. Lazo M, Hernaez R, Bonekamp S, et al. Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study. BMJ 2011;343:d6891. 442. Ивашкин В. Т. и соавт. Клинические рекомендации по диагностике и лечению неалкогольной жировой болезни печени Российского общества по изучению печени и Российской гастроэнтерологической ассоциации. РЖГГК 2016; 2:24 42. 443. Adams LA, Lymp JF, Sauver J, St, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005;129:113–121. 444. Marchesini G, Brizi M, Bianchi G, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes. 2001;50:1844–1850. 159 445. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15:539–553. 446. World Gastroenterology Organisation. Global Guidelines Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis, 2012; www.who.org 447. Драпкина О. М. Неалкогольная болезнь печени как компонент метаболического синдрома. Российские медицинские вести. 2010. № 2. С. 72–78. 448. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 2006;43(2 Suppl 1):S99–S112. 449. Kleiner DE, Brunt EM, Van Natta M et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–1321. 450. Pacana T, Fuchs M. The Cardiovascular Link to Nonalcoholic Fatty Liver Disease. Clin Liver Dis 2012:16:599–613. 451. Giovanni Targher, Christopher P. Day. Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease.N Engl J Med 2010;363:1341-50. 452. Hamaguchi M, Kojima T, Takeda N et al. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease.World J Gastroenterol 2007;13:1579-84. 453. Российские рекомендации. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза, V пересмотр. Москва, 2012. 454. Musso G, Gambino R, De Michieli F et al. Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology 2003; 37(4):909–16. 455. Ueno T, Sugawara S, Sujaku K et al. Therapeutic effects of diet and exercise in obese patients with fatty liver. J Hepatol 1997;27(1):103–07. 456. Dixon J, Bhathal P, Hughes N et al. Improvement in liver histological analysis with weight loss. Hepatology 2004;39(6):1647–54. 457. Atzui V, De LedinghenV, Oberti F et al. A randomized controlled trial of high-dosei ursodeoxycholic acid for nonalcoholic steatohepatitis. JHepatol 2011;54(5):1011–19. 458. Haedrich M, Dufour JF. UDCAforNASH: End of the story? JHepatol 2011;54(5):856–58 459. Chalasani N et al. HEPATOLOGY, 2012; Vol. 55, No. 6, 2005-23. 460. Bugianesi E, Gentilcore E, Manini R et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in non-alcoholic fatty liver disease. Am J Gastroenterol 2005;100(5):1082–90. 461. Belfort R, Harrison SA, Brown K et al. A placebo controlled trial of pioglitazone in subjects with non-alcoholic steatohepatitis. NEnglJMed 2006;355(22):2297–307. 462. Rakoski MO, Singal AG, Rogers MA et al. Meta-analysis: insulin sensitizers for the treatment of non-alcoholic steatohepatitis. AlimentPharmacolTher 2010;32(10):1211–21. 463. Лазебник Л. Б., Бордин Д. С., Кожурина Т. С. Больной с изжогой: тактика врача общей практики. Лечащий врач. 2009; 7:5-8. 464. Звенигородская Л. А., Бондаренко Е. Ю., Чурикова А. А. Особенности терапии гастроэзофагеальной рефлюксной болезни у больных с абдоминальным ожирением // Concilium medicum. 2010. № 8. С. 5–9. 160 465. Hampel H, Abraham NS, El-Serag HB. et al. Metaanalysis: obesity and the risk for gastroesophageal reflux disease and its complications // Ann. Intern. Med. 2005. Vol. 143. Р. 199–211. 466. El-Serag HB et al. Obesity is an independent risk factor for GERD symptoms and erosive esophagitis // The American journal of gastroenterology. 2005. Vol. 100. № 6. P. 1243–1250. 467. Белоусова Л. Н., Ткаченко Е. И., Успенский Ю. П. Гармонизация моторики пищевода у пациентов с ГЭРБ как основа повышения эффективности терапии // Гастроэнтерология Санкт Петербурга. 2009. № 1. С. 20–24. 468. Фадеенко Г. Д., Можина Т. Л. Лечение гастроэзофагеальной рефлюксной болезни у пациентов с ожирением: роль и место современного прокинетика итоприда гидрохлорида // Сучасна гастроентерол. 2011. № 1. С. 71–77. 469. Alberti K. et al. Harmonizing the Metabolic Syndrome A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity // Circulation. 2009. Vol. 120. № 16. P. 1640–1645. 470. Prasad H et al. Metabolic syndrome: definition and therapeutic implications // Postgraduate medicine. 2012. Vol. 124. № 1. P. 21–30. 471. Kassi E et al. Metabolic syndrome: definitions and controversies //BMC medicine. 2011. Vol. 9. № 1. P. 48. 472. Gallagher EJ, LeRoith D, Karnieli E. The metabolic syndrome—from insulin resistance to obesity and diabetes // Medical Clinics of North America. 2011. Vol. 95. № 5. P. 855–873. 473. Benetos A, Thomas F, Pannier B, Bean K, Jego B, Guize L. All-cause and cardiovascular mortality using the different definitions of metabolic syndrome. Am J Cardiol 2008; 102:188–191. 474. Nilsson PM, Engstrom G, Hedblad B. The metabolic syndrome and incidence of cardiovascular disease in nondiabetic subjects: a population-based study comparing three different definitions. DiabetMed 2007; 24:464–472. 475. Malnick SD, Knobler H. The medical consequences of obesity. Q J Med 2006;99:565–579. 476. Zhang Y, Jordan JM. Epidemiology of Osteoarthritis. ClinGeriatrMed 2010;26:3:355–369. 477. Felson DT, Zhang Y, Hannan MT. et al. Risk factors for incident radiographic knee osteoarthritis in the elderly: the Framingham Study. Arthritis Rheum 1997;40:728–733. 478. Spector TD, Hart DJ, Doyle DV. Incidence and progression of osteoarthritis in women with unilateral knee disease in the general population: the effect of obesity. Ann Rheum Dis 1994;53:565–568. 479. Hochberg MC, Lethbridge-Cejku M, Scott WW Jr. et al. The association of body weight, body fatness and body fat distribution with osteoarthritis of the knee: data from the Baltimore Longitudinal Study of Aging. JRheumatol 1995;22:488-493. 480. Gelber AC, Hochberg MC, Mead LA et al. Body mass index in young men and the risk of subsequent knee and hip osteoarthritis. Am J Med 1999;107:542- 548. 161 481. Manek Nisha J, Hart D, Spector TD, MacGregor AJ. The association of body mass index and osteoarthritis of the knee joint: an examination of genetic and environmental influences. ArthritRheum 2003;48:4:1024-1029. 482. Osteoarthritis and Obesity. A report by the Arthritis Research Campaign. 483. Cicuttini FM, Baker JR, Spector TD. The association of obesity with osteoarthritis of the hand and knee in women: a twin study. JRheumatol 1996;23:1221-1226. 484. Cooper C, Snow S, McAlindon TE. et al. Risk factors for the incidence and progression of radiographic knee osteoarthritis. Arthrit Rheum 2000;43:995- 1000. 485. Reijman M, Pols HA, Bergink AP. et al. Body mass index associated with onset and progression of osteoarthritis of the knee but not of the hip. The Rotterdam Study. Ann Rheum Dis 2007;66:158-162. 486. Pelletier JP, Martel-Pelletier J. Commentary The Novartis — ILAR Rheumatology Prize 2001 Osteoarthritis: from molecule to man. Arthritis Res 2002;4:13-19. 487. Sharma L, Berenbaum F (ed). Osteoarthritis: a companion to rheumatology. Philadelphia: Mos by Inc 2007. 488. Magliano M. Review Obesity and arthritis. Menopause International 2008;14:149-154. 489. Adamson J, Ebrahim S, Dieppe P, Hunt K. Prevalence and risk factors for joint pain among men and women in the West of Scotland Twenty-07 study. Ann Rheum Dis 2006;65:520-524. 490. Busija L, Hollingsworth B, Buchbinder R, Osborne RH. Role of age, sex, and obesity in the higher prevalence of arthritis among lower socioeconomic groups: a population-based survey. ArthritRheum 2007;57:553-561. 491. Becker J, Nora DB, Gomes I et al. An evaluation of gender, obesity, age and diabetes mellitus as risk factors for carpal tunnel syndrome. Clin Neurophysiol 2002;113:1429-1434. 492. Wendelboe AM, Hegmann KT, Gren LH. et al. Associations between body-mass index and surgery for rotator cuff tendonitis. JBone Joint Surg Am 2004;86A:743-747. 493. Leboeuf-Yde C, Kyvik KO, Bruun NH. Low backpain and lifestyle. Part II—Obesity. Information from a population-based sample of 29,242 twin subjects. Spine 1999;15:779-783. 494. Tepper S, Hochberg MC. Factors associated with hip osteoarthritis: data from the First National Health and Nutrition Examination Survey (NHANES-I). Am J Epidemiol 1993;137:1081-1088. 495. Cave MC, Hurt RT, Frazier TH et al. McClain and Stephen Obesity, Inflammation, and the Potential Application of Pharmaconutrition Nutr. Clin Pract 2008; 23(1):16–34. 496. Dumond H, Presle N, Terlain B et al. Evidence for a key role of leptin in osteoarthritis. ArthritRheumat 2003;48:11:3118-3129. 497. Gabriel Sh E, Michaud K. Review Epidemiological studies in incidence, prevalence, mortality and comorbidity of the rheumatic diseases. J Arthr Res Ther 2009;11:229. 498. Денисов Л. Н., Насонова B. A., Корешков Г. Г., Кашеварова Н. Г. Роль ожирения в развитии остеоартроза и сопутствующих заболеваний. Тер арх 2010;10:34-37. 499. Мендель О. И., Наумов А. В., Вёрткин А. Л. и др. Остеоартроз и сердечно-сосудистые заболевания у лиц пожилого возраста: клинические и патогенетические взаимосвязи. Успехи геронтол. 2010;23:2:304-314. 162 500. Kadam UT, Jordan K, Croft PR. Clinical comorbidity in patients with osteoarthritis: a case-control study of general practice consulters in England and Wales. Ann Rheum Dis 2004;63:4:408-414. 501. Hochberg MC. Mortality in osteoarthritis. Clin Exp Rheumat 2008;26:5: Suppl 51:120-124. 502. Jordan KM., Arden NK, Doherty M et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003;62:12:1145-1155. 503. Jordan KM, Arden NK, Doherty M et al. EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2005;64:669-681. 504. Zhang W, Moskowitz RW, Nuki G et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008;16:137-162. 505. Алексеева Л. И., Чичасова Н. В., Беневоленская Л. И. и др. Комбинированный препарат АРТРА при лечении остеоартроза. Тер арх 2005;11:69-75. 506. Kuk JL, Ardern CI. Influence of age on the association between various measures of obesity and all-cause mortality. J Am Geriatr Soc 2009; 57: 2077– 2084. 507. Roubenoff R. Sarcopenic obesity: the confluence of two epidemics. Obes Res 2004; 12: 887–88. 508. Stessman J, Jacobs JM, Ein-Mor E, Bursztyn M. Normal body mass index rather than obesity predicts greater mortality in elderly people: the Jerusalem longitudinal study. J Am Geriatr Soc 2009; 57: 2232–2238. 509. Schott AM, Cormier C, Hans D, Favier F, Hausherr E, Dargent-Molina P et al: How hip and whole-body bone mineral density predict hip fracture in elderly women: the EPIDOS Prospective Study. Osteoporos Int 1998; 8: 247–254. 510. Stenholm S, Harris TB, Rantanen T, Visser M, Kritchevsky SB, Ferrucci L. Sarcopenic obesity: definition, cause and consequences. Curr Opin Clin Nutr Metab Care 2008; 11: 693–70. 511. Miller SL, Wolfe RR. The danger of weight loss in the elderly. J Nutr Health Aging 2008; 12: 487–491. 512. Chau D, Cho LM, Jani P, St Jeor ST. Individualizing recommendations for weight management in the elderly. Curr Opin Clin Nutr Metab Care 2008; 11: 27– 31. 513. Fain JN, Madan AK, Hiler ML et al. Comparison of the release of adipokines by adipose tissue, adipose tissuematrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology2004; 145: 2273. 514. Calle EE et al: Overweight, obesity and mortality from cancer in a prospectively studied cohort of U.S. adults. NEJM 2003; 346: 1652–38. 515. Lileg B, Toplak H. Bedeutung der Adipositas in der Onkologie. Jatros — Diabetes&Stoffwechsel. 2006. 516. Kushner RF. Clinical assessment and management of adult obesity // Circulation. 2012. Vol. 126. № 24. P. 2870–2877. 517. Sarlio-Lähteenkorva S, Stunkard A, Rissanen A. Psychosocial factors and quality of life in obesity // International journal of obesity and related metabolic 163 disorders: journal of the International Association for the Study of Obesity. 1995. Vol. 19. P. S1–5. 518. Wadden TA et al. Comparison of Psychosocial Status in Treatment ‐ Seeking Women with Class III vs. Class I–II Obesity // Obesity. 2006. Vol. 14. № S3. P. 90S–98S. 519. Wadden TA et al. Psychosocial aspects of obesity and obesity surgery // Surgical Clinics of North America. 2001. Vol. 81. № 5. P. 1001–1024. 520. Murray D. Morbid obesity—psychosocial aspects and surgical interventions //AORN journal. 2003. Vol. 78. № 6. P. 990–995. 521. Wiltink J et al. Associations between depression and different measures of obesity (BMI, WC, WHtR, WHR) //BMC psychiatry. 2013. Vol. 13. № 1. P. 223. 522. Faith MS et al. Evidence for prospective associations among depression and obesity in population ‐based studies // Obesity Reviews. 2011. Vol. 12. № 5. P. e438–e453. 523. Preiss K, Brennan L, Clarke D. A systematic review of variables associated with the relationship between obesity and depression // Obesity Reviews. 2013. Vol. 14. № 11. P. 906–918. 524. Moon JW. The Effect of obesity, depression, self esteem, body image on adolescents' life satisfaction // The Journal of Korean Society for School & Community Health Education. 2012. Vol. 13. № 2. P. 60–80. 525. Puhl RM. Heuer CA. The stigma of obesity: are view and update. Obesity. 2009;17:941–964. 526. Nieman P et al. Psychosocial aspects of child and adolescent obesity // Paediatrics & child health. 2012. Vol. 17. № 4. P. 205. 527. Puhl RM, Brownell KD. Psychosocial origins of obesity stigma: toward changing a powerful and pervasive bias // Obesity reviews. 2003. Vol. 4. № 4. P. 213–227. 528. Салмина-Хвостова О. И., Лобыкина Е. Н., Симутина Н. С. Психологические аспекты низкой комплаентности лечения больных с избыточной массой тела и ожирением при нарушении пищевого поведения // Сиб вестн психиатр и наркол. 2008. Т. 2. С. 97–100. 529. Herpertz S et al. Does obesity surgery improve psychosocial functioning? A systematic review //International journal of obesity. 2003. Vol. 27. № 11. P. 1300–1314. 530. De Long NE et al. Perinatal Exposure to the Selective Serotonin Reuptake Inhibitor Fluoxetine Results in Hepatic Lipid Accumulation and Inflammation //Obesity and Inflammation. Endocrine Society, 2014. P. SUN-0910-SUN-0910. 531. Melendez G et al. Fluoxetine for adult overweight or obese people // The Cochrane Library. 2015. 532. Weingarten SR, Henning JM, Badamgarav E, Knight K, Hasselblad V, Gano A Jr, Ofman JJ. Interventions used in disease management programmes for patients with chronic illnesswhich ones work? Meta-analysis of published reports. BMJ 2002; 325:925. 533. Al ‐Daghri NM et al. Visceral adiposity index is highly associated with adiponectin values and glycaemic disturbances // European journal of clinical investigation. 2013. Vol. 43. № 2. P. 183–189. 534. Yang F et al. Visceral adiposity index may be a surrogate marker for the assessment of the effects of obesity on arterial stiffness. 2014. 535. Amato MC et al. Cut-off points of the visceral adiposity index (VAI) identifying a visceral adipose dysfunction associated with cardiometabolic risk in a Caucasian Sicilian population // Lipids Health Dis. 2011. Vol. 10. № 183. P. 1– 8. 164 536. Mohammadreza B et al. Prognostic significance of the complex “Visceral Adiposity Index” vs. simple anthropometric measures: Tehran lipid and glucose study //Cardiovasc Diabetol. 2012. Vol. 11. P. 20. 537. Guo F, Garvey WT. Development of a Weighted Cardiometabolic Disease Staging (CMDS) System for the Prediction of Future Diabetes // The Journal of Clinical Endocrinology & Metabolism. 2015. Vol. 100. № 10. P. 3871–3877. 538. Guo F, Moellering DR, Garvey WT. The progression of cardiometabolic disease: validation of a new cardiometabolic disease staging system applicable to obesity // Obesity. 2014. Vol. 22. № 1. P. 110–118. 539. World Health Organization et al. Interventions on diet and physical activity: what works: summary report. 2009. 540. Horn DB, Westman EC, Primack C, Schmidt SL, Ravasia D, McCarthy W, Ferguson U, Sabowitz BN, Scinta W, Bays HE. Obesity Algorithm, presented by the American Society of Bariatric Physicians, 2014–2015. 541. Нормы физиологических потребностей в энергии и пищевых веществах для различных групп населения Российской Федерации: Методические рекомендации 2.3.1.2432-08 от 18.12.2008 542. Аdapted from © Board of Regents of the University System of Georgia by Georgia State University, The American College of Sports Medicine (ACSM) and the U.S. Centers for Disease Control and Prevention (CDC) Recommendation 543. Zimmerman GL, Olsen CG, Bosworth MF. A ‘stages of change’ approach to helping patients change behavior. Am Fam Physician 2000;61(5):1409-16. |